RA Capital Management

To add a bio or update investment portfolio, please click update information.

Investment Portfolio

Artios Pharma lands £90m Series D led by SV Health Investors and RA Capital Management to advance DNA damage response therapeutics

18 Nov 2025

Artios Pharma lands £90m Series D led by SV Health Investors and RA Capital Management to advance DNA damage response therapeutics

Artios Pharma develops cancer treatments that target DNA damage response pathways, focusing on patient groups with limited existing treatment options.

Alchemab Therapeutics

9 Sept 2025

Alchemab Therapeutics raises £24m Series A extension led by Ono Venture Investment to advance AI-enabled antibody platform

Alchemab identifies naturally occurring protective antibodies using AI and patient data, developing new therapies based on disease resilience rather than traditional target discovery.

CellCentric

19 May 2025

CellCentric raises £90m Series C led by RA Capital and Forbion to advance first-in-class cancer drug

CellCentric is developing an oral cancer drug for multiple myeloma that targets a novel biological pathway, with ongoing clinical studies evaluating its use alone and in combination with existing therapies.

RA Capital Management